The PACAP receptor: a novel target for migraine treatment
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The PACAP receptor: a novel target for migraine treatment. / Schytz, Henrik W; Olesen, Jes; Ashina, Messoud.
I: Neurotherapeutics, Bind 7, Nr. 2, 01.04.2010, s. 191-6.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The PACAP receptor: a novel target for migraine treatment
AU - Schytz, Henrik W
AU - Olesen, Jes
AU - Ashina, Messoud
N1 - Copyright 2010 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier Inc. All rights reserved.
PY - 2010/4/1
Y1 - 2010/4/1
N2 - The origin of migraine pain has not yet been clarified, but accumulating data point to neuropeptides present in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is present in sensory trigeminal neurons and may modulate nociception at different levels of the nervous system. Human experimental studies have shown that PACAP-38 infusion induces marked dilatation of extracerebral vessels and delayed migraine-like attacks in migraine patients. PACAP selectively activates the PAC(1) receptor, which suggests a possible signaling pathway implicated in migraine pain. This review summarizes the current evidence supporting the involvement of PACAP in migraine pathophysiology and the PAC(1) receptor as a possible novel target for migraine treatment.
AB - The origin of migraine pain has not yet been clarified, but accumulating data point to neuropeptides present in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is present in sensory trigeminal neurons and may modulate nociception at different levels of the nervous system. Human experimental studies have shown that PACAP-38 infusion induces marked dilatation of extracerebral vessels and delayed migraine-like attacks in migraine patients. PACAP selectively activates the PAC(1) receptor, which suggests a possible signaling pathway implicated in migraine pain. This review summarizes the current evidence supporting the involvement of PACAP in migraine pathophysiology and the PAC(1) receptor as a possible novel target for migraine treatment.
U2 - http://dx.doi.org/10.1016/j.nurt.2010.02.003
DO - http://dx.doi.org/10.1016/j.nurt.2010.02.003
M3 - Journal article
VL - 7
SP - 191
EP - 196
JO - Neurotherapeutics
JF - Neurotherapeutics
SN - 1933-7213
IS - 2
ER -
ID: 34093581